Results 151 to 160 of about 97,001 (288)

Prognostic value of prothrombin time and activated partial thromboplastin time in patients with posttraumatic disseminated intravascular coagulation.

, 1994
Satoshi Gando, Satoshi Nanzaki, Takashi Kameue, Hiroshi Makise, Yoshimi Nakanishi   +4 more
openalex   +2 more sources

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population. [PDF]

Genes (Basel), 2022
Zhang F, Mu G, Liu Z, Xie Q, Zhang H, Zhou S, Wang Z, Hu K, Wang Z, Zhao X, Cui Y, Xiang Q.   +11 more
europepmc   +1 more source

A narrative literature review on the clinical utility of activated partial thromboplastin time and anti-factor Xa activity assays in cancer patients with anticoagulant therapy. [PDF]

Transl Cancer Res
Li HX, Song LH, Chen YH, Zhao J, Zhang XF.   +4 more
europepmc   +1 more source

Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis. [PDF]

Yonago Acta Med, 2022
Kato K, Hatayama Y, Shimohiro H, Ichikawa H, Fukuda T.   +4 more
europepmc   +1 more source

Fluorescence-Based Blood Coagulation Assay Device for Measuring Activated Partial Thromboplastin Time

, 2010
Magdalena Dudek, Nigel Kent, Kerstin M. Gustafsson, Tomas Lindahl, Anthony J. Killard   +4 more
openalex   +2 more sources

Deep learning model for screening causes of activated partial thromboplastin time prolongation using clot waveform analysis at multiple wavelengths. [PDF]

Sci Rep
Matsuda M, Shimomura D, Suzuki T, Tabuchi Y, Kurono H, Nishi K, Arai N, Hoshiyama Y, Kamioka M, Moriyama M, Matsumoto T.   +10 more
europepmc   +1 more source

Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children. [PDF]

J Pediatr Pharmacol Ther, 2023
Haftmann RJ, Pineda EM, Hall BA, Wilson MD, Mateev SN.   +4 more
europepmc   +1 more source

In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies

International Journal of Laboratory Hematology, 2016
P. Toulon, Y. Eloit, M. Smahi, C. Sigaud, D. Jambou, F. Fischer, A. Appert-Flory   +6 more
semanticscholar   +1 more source

Qualification of a select one‐stage activated partial thromboplastin time‐based clotting assay and two chromogenic assays for the post‐administration monitoring of nonacog beta pegol [PDF]

, 2017
Stefan Tiefenbacher, Rhea Bohra, Jean Amiral, Annette Bowyer, Steve Kitchen, A. Lochu, S. Rosén, Mirella Ezban   +7 more
openalex   +1 more source

Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis. [PDF]

Clin Appl Thromb Hemost, 2023
Yuan Y, Li X, Qiu F.
europepmc   +1 more source